Impact of disease-modifying therapies on humoral and cellular immune-responses following SARS-CoV-2 vaccination in MS patients
The impact of distinct disease-modifying therapies (DMTs) on severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccination efficacy in patients with multiple sclerosis (MS) is still enigmatic. In this prospective comparative study, we investigated humoral and cellular immune-responses in...
| Verfasser: | |
|---|---|
| FB/Einrichtung: | FB 05: Medizinische Fakultät |
| Dokumenttypen: | Artikel |
| Medientypen: | Text |
| Erscheinungsdatum: | 2022 |
| Publikation in MIAMI: | 30.08.2023 |
| Datum der letzten Änderung: | 30.08.2023 |
| Angaben zur Ausgabe: | [Electronic ed.] |
| Quelle: | CTS Clinical and Translational Science 15 (2022) 7, 1606-1612 |
| Fachgebiet (DDC): | 610: Medizin und Gesundheit |
| Lizenz: | CC BY-NC-ND 4.0 |
| Sprache: | English |
| Förderung: | Finanziert über die DEAL-Vereinbarung mit Wiley 2019-2022. |
| Format: | PDF-Dokument |
| URN: | urn:nbn:de:hbz:6-89928468200 |
| Weitere Identifikatoren: | DOI: 10.17879/39938516875 |
| Permalink: | https://nbn-resolving.de/urn:nbn:de:hbz:6-89928468200 |
| Verwandte Dokumente: |
|
| Onlinezugriff: | 10.1111_cts.13256.pdf |
The impact of distinct disease-modifying therapies (DMTs) on severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccination efficacy in patients with multiple sclerosis (MS) is still enigmatic. In this prospective comparative study, we investigated humoral and cellular immune-responses in patients with MS receiving interferon beta, natalizumab, and ocrelizumab pre-vaccination and 6 weeks post second SARS-CoV-2 vaccination. Healthy individuals and interferon beta-treated patients generated robust humoral and cellular immune-responses. Although humoral immune responses were diminished in ocrelizumab-treated patients, cellular immune-responses were reduced in natalizumab-treated patients. Thus, both humoral and cellular immune responses should be closely monitored in patients on DMTs. Whereas patients with a poor cellular immune-response may benefit from additional vaccination cycles, patients with a diminished humoral immune-response may benefit from a treatment with SARS-CoV-2 antibodies in case of an infection.